D.C. Mun. Regs. tit. 22, r. 22-B502

Current through Register Vol. 71, No. 49, December 6, 2024

Rule 22-B502 - DISPOSAL OF UNUSED PHARMACEUTICAL PRODUCTS

502.1

Pharmaceutical products may be disposed of through:

(a) A waste to energy program;

(b) A pharmaceutical waste container with appropriate procedures for disposal; or

(c) Recommended procedures as published by the FDA and DEA.

502.2

Those pharmaceutical products which are defined as controlled substances under federal or District law shall be managed in accordance with federal and District laws and regulations.

502.3

Those pharmaceutical products which are defined as hazardous waste under federal or District law shall be managed in accordance with federal and District laws and regulations.

502.4

All antineoplastic and cytotoxic drugs shall be treated as hazardous waste and

managed and disposed of in accordance with the applicable federal and District laws and regulations.

502.5

A health care facility may choose to manage its pharmaceutical waste at a more stringent or higher level of waste management than that required under applicable District or federal laws and regulations.

502.6

All pharmaceutical waste shall be separated from active pharmaceutical stock and clearly labeled as "pharmaceutical waste."

502.7

Pharmaceutical waste shall not be combined with other forms of waste unless the pharmaceutical waste is first denatured as recommended by both the FDA and DEA.

D.C. Mun. Regs. tit. 22, r. 22-B502

Final Rulemaking published at 60 DCR 9354 (June 21, 2013)

Authority: Sections 4 and 5 of the District of Columbia Unused Pharmaceutical Safe Disposal Act of 2009, (the Act), effective March 5, 2010 (D.C. Law 18-112, D.C. Official Code §§ 48-851.03 and 48-851.04 (2012 Repl.)) and Mayor's Order 2011-90, dated May 6, 2011.